[go: up one dir, main page]

ECSP22010121A - Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos - Google Patents

Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos

Info

Publication number
ECSP22010121A
ECSP22010121A ECSENADI202210121A ECDI202210121A ECSP22010121A EC SP22010121 A ECSP22010121 A EC SP22010121A EC SENADI202210121 A ECSENADI202210121 A EC SENADI202210121A EC DI202210121 A ECDI202210121 A EC DI202210121A EC SP22010121 A ECSP22010121 A EC SP22010121A
Authority
EC
Ecuador
Prior art keywords
microtubule
therapeutics
targeting agents
peptide conjugates
conjugates
Prior art date
Application number
ECSENADI202210121A
Other languages
English (en)
Inventor
Daniel Richard Marshall
Robert John Maguire
Robert A Volkmann
Johanna Marie Csengery
Original Assignee
Cybrexa 3 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cybrexa 3 Inc filed Critical Cybrexa 3 Inc
Publication of ECSP22010121A publication Critical patent/ECSP22010121A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a conjugados peptídicos de agentes dirigidos a microtúbulos tales como derivados de maitansinoide que son útiles para el tratamiento de enfermedades tal como cáncer.
ECSENADI202210121A 2019-07-10 2022-02-09 Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos ECSP22010121A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962872638P 2019-07-10 2019-07-10
US202063041324P 2020-06-19 2020-06-19

Publications (1)

Publication Number Publication Date
ECSP22010121A true ECSP22010121A (es) 2022-05-31

Family

ID=71944331

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202210121A ECSP22010121A (es) 2019-07-10 2022-02-09 Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos

Country Status (19)

Country Link
US (2) US11555019B2 (es)
EP (1) EP3996749A1 (es)
JP (1) JP7675060B2 (es)
KR (1) KR20220051332A (es)
CN (1) CN114302744B (es)
AU (1) AU2020311925A1 (es)
BR (1) BR112022000297A2 (es)
CA (1) CA3146385A1 (es)
CL (1) CL2022000043A1 (es)
CO (1) CO2022001315A2 (es)
CR (1) CR20220057A (es)
EC (1) ECSP22010121A (es)
IL (1) IL289659B1 (es)
MX (1) MX2022000450A (es)
MY (1) MY209459A (es)
PE (1) PE20220485A1 (es)
PH (1) PH12022550037A1 (es)
TW (1) TW202116356A (es)
WO (1) WO2021007402A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020013672A2 (pt) 2018-01-05 2020-12-01 Cybrexa 1, Inc. compostos, composições, e métodos para tratamento de doenças que envolvem tecidos afetados por ácidos ou hipoxia
CA3146560A1 (en) 2019-07-10 2021-01-14 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
JP7675060B2 (ja) 2019-07-10 2025-05-12 サイブレクサ ３，インコーポレイテッド 治療薬としての微小管標的化剤のペプチドコンジュゲート
PE20240119A1 (es) 2021-01-08 2024-01-22 Cybrexa 2 Inc Proceso para preparar un resto enlazador de conjugados
CN118574642A (zh) * 2021-11-17 2024-08-30 赛博克萨4公司 作为治疗剂的肽微管蛋白抑制剂的肽缀合物

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637770A (en) 1991-01-16 1997-06-10 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
CA2225465A1 (en) 1995-08-02 1997-02-13 Newcastle University Ventures Limited Benzimidazole compounds
DK0897924T3 (da) 1996-04-26 2001-11-19 Daiichi Seiyaku Co Fremgangsmåde til fremstilling af tetrahydroindoliziner
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
IN189180B (es) 1997-07-09 2003-01-04 Chong Kun Dang Corp
MY132496A (en) 1998-05-11 2007-10-31 Vertex Pharma Inhibitors of p38
KR100581443B1 (ko) 1998-05-22 2006-05-23 다이이찌 세이야꾸 가부시기가이샤 약물복합체
CA2348931A1 (en) 1998-10-30 2000-05-11 Daiichi Pharmaceutical Co., Ltd. Dds compound and method for measurement thereof
JP2002528531A (ja) 1998-11-03 2002-09-03 ビーエーエスエフ アクチェンゲゼルシャフト 置換２−フェニルベンズイミダゾール、その製造法および使用
WO2000042040A1 (en) 1999-01-11 2000-07-20 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(adp-ribose) polymerases
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6699876B2 (en) 1999-11-18 2004-03-02 Les Laboratoires Servier Camptothecin analogue compounds
BR0016328A (pt) 1999-12-13 2002-08-27 Lilly Co Eli Pró-drogas de fosfato de pseudomicina
WO2001068145A2 (en) * 2000-03-15 2001-09-20 Bristol-Myers Squibb Pharma Company Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
KR20030023697A (ko) 2000-07-13 2003-03-19 다이이찌 세이야꾸 가부시기가이샤 Ｄｄｓ 화합물을 함유하는 의약 조성물
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
CA2476182A1 (en) 2002-03-01 2003-09-12 The Administrators Of The Tulane Educational Fund Conjugates of therapeutic or cytotoxic agents and biologically active peptides
MXPA04008999A (es) 2002-03-20 2004-12-07 Squibb Bristol Myers Co Profarmacos de fosfato de fluorooxindoles.
ES2357057T3 (es) 2002-04-30 2011-04-15 Kudos Pharmaceuticals Limited Derivados de ftalazinona.
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
EP1611137A1 (en) 2003-03-31 2006-01-04 Pfizer Inc. Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
EP2281577B1 (en) 2003-05-14 2016-11-16 ImmunoGen, Inc. Drug conjugate composition
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
CA2525130C (en) 2003-05-20 2014-04-15 Immunogen, Inc. Improved cytotoxic agents comprising new maytansinoids
PT1660095E (pt) 2003-07-25 2010-04-19 Pfizer Inibidores tricíclicos de parp
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
NZ547984A (en) 2003-12-01 2009-03-31 Kudos Pharm Ltd DNA damage repair inhibitors for treatment of cancer
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US8288557B2 (en) 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
WO2006033007A2 (en) 2004-09-22 2006-03-30 Pfizer Inc. Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
WO2006033003A1 (en) 2004-09-22 2006-03-30 Pfizer, Inc. Method of preparing poly(adp-ribose) polymerases inhibitors
EP1793830A2 (en) 2004-09-22 2007-06-13 Pfizer, Inc. Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor
EA013323B1 (ru) 2004-12-09 2010-04-30 Сентокор, Инк. Иммуноконъюгаты против интегрина, способы и варианты применения
AU2006206428B2 (en) 2005-01-18 2009-07-16 The Board Of Governors For Higher Education Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide
US7301019B2 (en) 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters
EP2468304A3 (en) 2005-02-11 2012-09-26 ImmunoGen, Inc. Process for preparing stable drug conjugates
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
BRPI0608175A2 (pt) 2005-04-15 2009-11-10 Immunogen Inc método de eliminação de população de células heterogêneas ou mistas em tumores, assim como compostos maitansinóides
CA2893252C (en) 2005-08-24 2018-05-29 Immunogen, Inc. Process for preparing antibody maytansinoid conjugates
CN101316834A (zh) 2005-09-29 2008-12-03 艾博特公司 在2位取代有苯基的1h-苯并咪唑-4-甲酰胺是强效parp抑制剂
PL1945647T3 (pl) 2005-11-08 2012-04-30 Immunogen Inc Procesy wytwarzania maytansinolu
RS53082B (sr) 2006-01-17 2014-06-30 Abbvie Bahamas Ltd. Kombinovana terapija sa parp inhibitorima
WO2007131133A2 (en) 2006-05-04 2007-11-15 Genentech, Inc. Methods and compositions relating to zpa polypeptides
TWI404716B (zh) 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
EP2109608B1 (en) 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
WO2008114114A2 (en) 2007-03-16 2008-09-25 Pfizer Products Inc. Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition
CA2690943A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US8067613B2 (en) 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
EP3838298B1 (en) 2007-08-17 2025-02-26 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
EP2276506A4 (en) 2008-04-30 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
ES2617619T3 (es) 2008-06-05 2017-06-19 Janssen Pharmaceutica, N.V. Combinaciones de fármacos que comprenden un inhibidor de DGAT y un agonista de PPAR
KR102444399B1 (ko) 2009-06-03 2022-09-16 이뮤노젠 아이엔씨 메이탄시노이드의 제조방법
US9353140B2 (en) 2009-11-25 2016-05-31 Academia Sinica BQC-G, a tumor-selective anti-cancer prodrug
JP5745283B2 (ja) 2010-02-12 2015-07-08 ファイザー・インク ８−フルオロ−２−｛４−［（メチルアミノ）メチル］フェニル｝−１，３，４，５−テトラヒドロ−６Ｈ−アゼピノ［５，４，３−ｃｄ］インドール−６−オンの塩および多形体
US20120322741A1 (en) 2010-02-25 2012-12-20 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
MX2012011171A (es) 2010-03-31 2013-02-01 Gilead Pharmasset Llc Fosforamidatos de nucleosido.
EP2566335B1 (en) 2010-05-05 2016-06-29 Prolynx Llc Controlled release of active compounds from macromolecular conjugates
WO2012047354A2 (en) 2010-07-13 2012-04-12 Rhode Island Board Of Governors For Higher Education Environmentally sensitive compositions
EP2603201B1 (en) 2010-08-13 2020-03-11 Rhode Island Board of Governors for Higher Education Liposome compositions and methods of use thereof
MX2013005046A (es) 2010-11-03 2013-12-12 Immunogen Inc Agentes citotoxicos que comprenden nuevos derivados de ansamitocina.
CN107537040A (zh) 2011-03-29 2018-01-05 伊缪诺金公司 通过一步法制备类美登素抗体缀合物
SG193996A1 (en) 2011-03-29 2013-11-29 Immunogen Inc Preparation of maytansinoid antibody conjugates by a one-step process
DK2750713T3 (en) 2011-10-14 2015-12-21 Medimmune Ltd PYRROLOBENZODIAZEPINS AND CONJUGATES THEREOF
KR102853456B1 (ko) 2012-10-11 2025-09-01 다이이찌 산쿄 가부시키가이샤 글리신아미드 화합물의 제조 방법
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
US9180203B2 (en) 2012-10-23 2015-11-10 The Johns Hopkins University Self-assembling drug amphiphiles and methods for synthesis and use
WO2014093343A2 (en) 2012-12-10 2014-06-19 Massachusetts Institute Of Technology Multistage nanoparticle drug delivery system for the treatment of solid tumors
US9814784B2 (en) 2013-01-03 2017-11-14 Celltrion, Inc. Antibody-linker-drug conjugate, preparation method therefor, and anticancer drug composition containing same
WO2014134483A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
CN111569086B (zh) 2013-12-19 2024-06-21 西雅图基因公司 与目标-药物偶联物并用的亚甲基氨基甲酸酯连接物
US20180163271A1 (en) 2014-01-16 2018-06-14 Clovis Oncology, Inc. Use of PARP Inhibitors to Treat Breast or Ovarian Cancer Patients Showing a Loss of Heterozygosity
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
JP2017114763A (ja) 2014-03-26 2017-06-29 第一三共株式会社 抗ｃｄ９８抗体−薬物コンジュゲート
AU2015245122B2 (en) 2014-04-10 2019-10-24 Daiichi Sankyo Company, Limited Anti-HER3 antibody-drug conjugate
US11185594B2 (en) 2014-04-10 2021-11-30 Daiichi Sankyo Company, Limited (Anti-HER2 antibody)-drug conjugate
US20170151339A1 (en) 2014-06-30 2017-06-01 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
CN113209033A (zh) 2014-08-22 2021-08-06 克洛维斯肿瘤有限公司 Rucaparib的高剂量强度片剂
AU2015318018B2 (en) 2014-09-16 2017-05-11 Synermore Biologics (Suzhou) Co. Ltd. Anti-EGFR antibody and uses of same
PT3204018T (pt) 2014-10-07 2021-11-12 Immunomedics Inc Uso neoadjuvante de conjugados anticorpo-fármaco
AU2015349985A1 (en) 2014-11-19 2017-05-25 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
KR102407261B1 (ko) 2015-02-27 2022-07-06 서울대학교산학협력단 나노 항암제형 및 그 제조 방법
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
CN108473538B (zh) 2015-10-28 2022-01-28 塔弗达治疗有限公司 Sstr靶向缀合物及其颗粒和制剂
US10435428B2 (en) 2015-11-24 2019-10-08 Theravance Biopharma R&D Ip, Llc Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease
KR102498258B1 (ko) 2016-01-20 2023-02-10 삼성디스플레이 주식회사 표시 장치
US20170267727A1 (en) 2016-03-04 2017-09-21 Lehigh University Conjugates of pH Low Insertion Peptide and Monomethyl Auristatins in the Treatment of Solid Tumors
JP2019510085A (ja) 2016-03-08 2019-04-11 ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療のためのナノ粒子ならびに方法および化合物
EP3442592A4 (en) 2016-04-13 2019-11-27 Tarveda Therapeutics, Inc. NEUROTENSIN RECEPTOR BINDING CONJUGATES AND FORMULATIONS THEREOF
GB201608885D0 (en) 2016-05-20 2016-07-06 Univ Birmingham Treatment
US20190133980A1 (en) 2016-06-02 2019-05-09 Yale University Compositions and methods for targeting and treating homologous recombination-deficient tumors
US20210283281A1 (en) 2016-07-29 2021-09-16 Memorial Sloan Kettering Cancer Center Radiolabeled ligands for targeted pet/spect imaging and methods of their use
PT3502122T (pt) 2016-08-16 2021-11-25 Aist Péptido que visa tumor maligno
US11779662B2 (en) * 2016-09-22 2023-10-10 University Of Rhode Island Board Of Trustees Fluorescent compound comprising a fluorophore conjugated to a pH-triggered polypeptide
JP7058666B2 (ja) 2016-11-25 2022-04-22 マブウェル （シャンハイ） バイオサイエンス カンパニー リミテッド 抗体－薬物複合体化のための二置換マレインアミドリンカーならびにその調製方法および使用
EP3554638B1 (en) 2016-12-19 2022-02-02 Morehouse School of Medicine Compositions and methods for treating diseases by inhibiting exosome release
EP3634498A4 (en) 2017-06-09 2021-08-25 Rhode Island Council on Postsecondary Education BOUND COMPOUNDS AND OTHER PH ACTIVATED COMPOUNDS
KR102422860B1 (ko) 2017-08-31 2022-07-19 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 신규 제조 방법
BR112020013672A2 (pt) 2018-01-05 2020-12-01 Cybrexa 1, Inc. compostos, composições, e métodos para tratamento de doenças que envolvem tecidos afetados por ácidos ou hipoxia
KR20200109345A (ko) 2018-01-12 2020-09-22 프로린크스 엘엘시 상승적 암 치료
HRP20230787T1 (hr) 2018-05-18 2023-10-27 Glycotope Gmbh Anti-muc1 antitijelo
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
CN109232719B (zh) 2018-09-21 2021-06-29 中国科学院理化技术研究所 一种pH响应的抗菌肽及其制备方法和应用
WO2020160009A1 (en) * 2019-01-28 2020-08-06 Rhode Island Council On Postsecondary Education Phlip® targeted delivery of potent cytotoxic compounds
KR102679892B1 (ko) 2019-03-29 2024-07-02 메디뮨 리미티드 화합물 및 이의 접합체
CA3146560A1 (en) 2019-07-10 2021-01-14 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
JP7675060B2 (ja) 2019-07-10 2025-05-12 サイブレクサ ３，インコーポレイテッド 治療薬としての微小管標的化剤のペプチドコンジュゲート
PE20240119A1 (es) 2021-01-08 2024-01-22 Cybrexa 2 Inc Proceso para preparar un resto enlazador de conjugados
CN117897175A (zh) 2021-04-29 2024-04-16 美商斯布雷克萨二号公司 拓扑异构酶i抑制剂的肽缀合物的给药方案
CN118574642A (zh) 2021-11-17 2024-08-30 赛博克萨4公司 作为治疗剂的肽微管蛋白抑制剂的肽缀合物

Also Published As

Publication number Publication date
PE20220485A1 (es) 2022-04-04
CA3146385A1 (en) 2021-01-14
TW202116356A (zh) 2021-05-01
WO2021007402A1 (en) 2021-01-14
EP3996749A1 (en) 2022-05-18
US12234212B2 (en) 2025-02-25
MX2022000450A (es) 2022-04-25
US11555019B2 (en) 2023-01-17
CN114302744B (zh) 2025-08-26
JP7675060B2 (ja) 2025-05-12
PH12022550037A1 (en) 2023-04-12
KR20220051332A (ko) 2022-04-26
US20210009536A1 (en) 2021-01-14
CR20220057A (es) 2022-07-19
CL2022000043A1 (es) 2022-08-19
IL289659B1 (en) 2026-01-01
BR112022000297A2 (pt) 2022-03-15
JP2022541747A (ja) 2022-09-27
CN114302744A (zh) 2022-04-08
CO2022001315A2 (es) 2022-05-10
AU2020311925A1 (en) 2022-02-03
US20240067616A1 (en) 2024-02-29
MY209459A (en) 2025-07-09
IL289659A (en) 2022-03-01

Similar Documents

Publication Publication Date Title
CO2022001316A2 (es) Conjugados peptídicos de citotoxinas como terapéuticos
ECSP22010121A (es) Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos
CO2022000040A2 (es) Vesículas extracelulares microbianas procesadas
BR112018077492A2 (pt) métodos de tratamento de câncer de ovário
ECSP17073191A (es) Compuestos heterocíclicos como inhibidores de lsd1
MX2020001360A (es) Macrociclos de diarilo como moduladores de la proteina quinasa.
AR088694A1 (es) Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos
CO2022001083A2 (es) Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados
MX2018001723A (es) Conjugados farmaco-multiligando y usos de los mismos.
ECSP20061378A (es) COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-gamma
MX2022014277A (es) Metodos para una mejor administracion de agentes activos a tumores.
CO2020000227A2 (es) Moduladores de nlrp3
MX2020010408A (es) Conjugados de anticuerpo-farmaco y sus usos para el tratamiento del cancer.
MX2022014231A (es) Conjugados de anticuerpo-farmaco que se enfocan a la uparap.
CO2019002523A2 (es) Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica
CO2024007413A2 (es) Conjugados peptídicos de inhibidores de tubulina peptídica como agentes terapéuticos
MX2020004678A (es) Uso de profarmacos de riluzol para tratar ataxias.
CO2020016131A2 (es) Agonistas de tlr7
CL2018000726A1 (es) Tratamiento con conjugado syd985 de pacientes con cáncer resistente al tratamiento con t-dm1
BR112022022590A2 (pt) Formulações farmacêuticas de acetato de abiraterona e niraparibe
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
AR120058A1 (es) Vesículas extracelulares microbianas procesadas
MX390150B (es) Obtencion de triterpenos del tipo lupano a partir de phoradendron vernicosum y su uso en el tratamiento de cancer.